Board of Directors

C. Raymond Larkin, Jr., has served as a director of Align Technology since March 2004. In February 2006, Mr. Larkin was appointed as Chairman of the Board. He currently serves as a principal of Group Outcome L.L.C., a merchant banking firm concentrating on medical technologies. From 2001 to 2007, he served as a part time Venture Partner at Cutlass Capital, a venture capital firm. Prior to Group Outcome, Mr. Larkin was Chairman and CEO at Eunoe Inc., an investigative device for slowing and stopping progression of Alzheimer's disease. Prior to that, he was President and Chief Executive Officer of Nellcor Puritan Bennett, Inc., one of the world's preeminent respiratory products companies. Under Mr. Larkin's leadership over 15 years, Nellcor grew to nearly $1 billion in revenues through the development and introduction of pulse oximetry into worldwide use for patient safety monitoring, setting the standard of care for the respiratory-impaired patient. Mr. Larkin also held positions of increasing responsibility at Bentley Laboratories/American Hospital Supply from 1976 to 1983. He serves as chairman of the board of Shockwave Medical, Inc., a cardiovascular medical device company. Mr. Larkin received his B.S. degree in Industrial Management from LaSalle University.

Kevin J. Dallas has served as a director of Align Technology since May 2018. Mr. Dallas served as President and Chief Executive Officer at Wind River, a company whose software deploys loT systems, from 2020 until its acquisition by Aptiv in 2022. With more than 25 years of experience driving digital innovation and growth at technology companies, Kevin Dallas was responsible for all aspects of Wind River’s business globally.

He joined Wind River from Microsoft, where he last served as the corporate vice president for cloud and AI business development. At Microsoft, he led a team creating partnerships that enabled the digital transformation of customers and partners across a range of industries including connected/autonomous vehicles, industrial IoT, discrete manufacturing, retail, financial services, media and entertainment, and healthcare.

Prior to joining Microsoft in 1996, he held roles at NVIDIA Corporation and National Semiconductor (now Texas Instruments Inc.) in the U.S., Europe, and the Middle East in roles that included microprocessor design, systems engineering, product management, and end-to-end business leadership. He holds a B.S.c. degree in electrical and electronic engineering from Staffordshire University, Stoke-on-Trent, Staffordshire, England.

Joseph Lacob has served as a director of Align Technology since August 1997 and was a partner of Kleiner Perkins Caufield & Byers (KPCB), a venture capital firm from1987 to 2018. In 2011, Mr. Lacob acquired The Golden State Warriors of the National Basketball Association. He is currently the Governor, Co-Executive Chairman and CEO of the Warriors. Prior to joining KPCB in 1987, Mr. Lacob was an executive with Cetus Corporation (now Chiron), FHP International, a health maintenance organization (HMO), and the management consulting firm of Booz, Allen & Hamilton. Since joining KPCB in 1987, Mr. Lacob has been closely involved with KPCB's investments in more than 50 life science companies, including the startup or incubation of a dozen ventures, and with KPCB's medical technology practice, which includes more than 30 therapeutic and diagnostic medical device companies. He was previously on the board of directors of Orexigen Therapeutics, a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. He serves on the board of NeuroPace, a medical device company specializing in the treatment of adults with drug-resistant focal epilepsy. Mr. Lacob received his B.S. degree in Biological Sciences from the University of California at Irvine, his master’s degree in public health from the University of California at Los Angeles and his M.B.A. from Stanford University

George J. Morrow has served as a director of Align Technology since February 2006. From February 2011 until January 2013, Mr. Morrow served as a consultant to Amgen Inc., a global biotechnology company. From 2003 until his retirement in February 2011, he was the Executive Vice President, Global Commercial Operations at Amgen Inc., where he also served as Executive Vice President of Worldwide Sales and Marketing between 2001 and 2003. From 1992 to 2001, Mr. Morrow held multiple leadership positions at GlaxoSmithKline Inc. and its subsidiaries, including President and Chief Executive Officer of Glaxo Wellcome Inc. He serves  on the board of directors for Neurocrine Biosciences, a company developing treatments for neurological and endocrine-related diseases and disorders. Mr. Morrow holds a B.S. degree in Chemistry from Southampton College, Long Island University, a M.S. degree in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University.

Anne M. Myong has served as a director of Align Technology since August 2019. Ms. Myong is currently a consultant at Amyris, Inc., a biotechnology company serving the beauty, health, and wellness markets. She previously served as its President. From 2014-17, Ms. Myong served as the Senior Vice President and Chief Financial Officer at Walmart Global eCommerce, where she accelerated the growth and digital transformation of Walmart’s retail and e-commerce operations in the United States, China and Brazil. Earlier, she was Senior Vice President, Chief Financial and Administrative Officer, Walmart China Retail. In that role, she was the senior operations and finance executive leading a retail operation of over 400 stores and 100,000 associates across China. Prior to her roles at Walmart, Ms. Myong was Vice President and CFO of Agilent Technologies China, where she was the senior finance executive of Agilent’s fastest growing and second largest market.

Ms. Myong holds an M.B.A. degree from Harvard Business School and a B.B.A. degree in Computer Information Systems from James Madison University.
 

Andrea L. Saia has served as a director of Align Technology since July 2013. Ms. Saia has extensive global experience within the healthcare, medical device and consumer products industries. Ms. Saia previously served as the Global Head of Alcon Vision Care, a $10 billion division of  Novartis AG from 2011 to 2012 and as President and Chief Executive Officer of CibaVision Corporation, a $2billion subsidiary of Novartis from 2008 to 2011. She also held a number of other senior leadership roles at CibaVision from 2002 to 2007, including President of Europe, Middle East, and Africa, President of the Global Lens Business and Global Head of Marketing. Prior to CibaVision, she held a variety of senior executive leadership roles with Unilever, Procter & Gamble and Revlon.

Ms. Saia earned an M.B.A. degree from J.L. Kellogg Graduate School of Business and a B.S. degree in Business Administration from Miami University. Ms. Saia serves on the board of directors of medical devices company LivaNova PLC, which develops devices for cardiac surgery and neuromodulation, and Outset Medical, Inc., a medical technology company reimagining dialysis for patients and providers. She also served on the board of Coca-Cola Enterprises, Inc., the marketer, producer and distributor of Coca-Cola products in European markets. She is a member of the National Association of Corporate Directors, Women Corporate Directors, and the Signature Program. Andrea serves on the Advisory Board of the Farmer Business School at Miami University.
 

Sue Siegel has been a CEO, VC, and board member for big and small, private and public, and nonprofit organizations. She is a visionary leader known for identifying and seizing transformative opportunities that help organizations build new markets, create stakeholder returns, and impact lives. Sue directs her passion towards unlocking untapped potential to drive growth in individuals, industries, and across teams.

Sue has served for 20+ years for over a dozen public and private companies. Her current board portfolio includes Illumina, Align and  Nevro, and she is the Chairman of the Board of  MIT’s The Engine. Her public service includes serving on President Obama’s Working Group for starting the Precision Medicine Initiative, as a founding board member of the National Center for Advancing Translational Science, and as a selection judge for White House Fellows across administrations. She served on the nonprofit boards of the National Venture Capital Association and Silicon Valley’s Tech Interactive.

Previously, Sue served as GE’s Chief Innovation Officer, CEO of GE Ventures & Licensing, and CEO of Healthymagination. Before GE, she was a VC General Partner at Mohr Davidow Ventures, leading investments in Life Sciences & Health. During the early days of the human genome project, Sue led Affymetrix, one of the fastest growing genomics companies of its time. She led it from a pre-revenue startup to a multi-billion publicly listed company that helped shape the emerging genomics industry, including addressing the bioethical issues of its day. Her corporate career began after academic graduate work in molecular biology and biochemistry, doing stints at BioRad, DuPont, and Amersham, where she held executive leadership roles. Currently, Sue is a senior lecturer on Entrepreneurship at MIT Sloan School of Management.

Sue has been recognized in Fortune’s “34 Leaders Who Are Changing Health Care,” as one of “The 100 Most Influential Women in Silicon Valley” and was awarded the “Lifetime Achievement Award” by Global Corporate Venture in 2020. She is an Aspen Institute Henry Crown Fellow and is a featured “Multiplier” in the bestselling book: “Multipliers: How the Best Leaders Make Everyone Smarter.”